| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef70b43d229e99fa27d7991a26b6add9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_050fc7b82c5d17d9aeb63a7cdcc546b3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5146 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6901
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5123
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6923
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 |
| filingDate |
2020-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e137ac9c434953b99e15b2e1d880aa8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_832275f2a197f2b18263ba2a6cae91c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc9a7f667dd55f9311e5e29a4e86a7a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7f0f1a1e468732fe708920d73e98c98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3984c5eab9651b89b0daf005c926f9c1 |
| publicationDate |
2020-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020149657-A2 |
| titleOfInvention |
Drug delivery system and method |
| abstract |
A drug delivery system and method is provided. The drug delivery system comprises: a nanoparticle associated with a first functional group and having a drug loaded thereonto; an antibody associated with a second functional group reactive to the first functional group; and a carrier cell containing an antigen protein capable of being bound to by the antigen. The drug delivery method comprises the steps of: in vivo introducing a nanoparticle bearing a first functional group and having a drug loaded thereonto and an antibody bearing a second functional group reactive to the first functional group; and binding the antibody to the antigen protein of the carrier cell present in vivo and associating the nanoparticle with the antibody through the reaction between the first functional group and the second functional group. |
| priorityDate |
2019-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |